157 related articles for article (PubMed ID: 17008819)
1. A poor metabolizer for cytochromes P450 2D6 and 2C19: a case report on antidepressant treatment.
Johnson M; Markham-Abedi C; Susce MT; Murray-Carmichael E; McCollum S; de Leon J
CNS Spectr; 2006 Oct; 11(10):757-60. PubMed ID: 17008819
[TBL] [Abstract][Full Text] [Related]
2. Metabolic ratios of psychotropics as indication of cytochrome P450 2D6/2C19 genotype.
van der Weide J; van Baalen-Benedek EH; Kootstra-Ros JE
Ther Drug Monit; 2005 Aug; 27(4):478-83. PubMed ID: 16044105
[TBL] [Abstract][Full Text] [Related]
3. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.
de Leon J; Susce MT; Murray-Carmichael E
Mol Diagn Ther; 2006; 10(3):135-51. PubMed ID: 16771600
[TBL] [Abstract][Full Text] [Related]
4. Maribavir pharmacokinetics and the effects of multiple-dose maribavir on cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-acetyltransferase-2, and xanthine oxidase activities in healthy adults.
Ma JD; Nafziger AN; Villano SA; Gaedigk A; Bertino JS
Antimicrob Agents Chemother; 2006 Apr; 50(4):1130-5. PubMed ID: 16569820
[TBL] [Abstract][Full Text] [Related]
5. Hydroxylation and demethylation of the tricyclic antidepressant nortriptyline by cDNA-expressed human cytochrome P-450 isozymes.
Olesen OV; Linnet K
Drug Metab Dispos; 1997 Jun; 25(6):740-4. PubMed ID: 9193876
[TBL] [Abstract][Full Text] [Related]
6. Poor metabolizers at the cytochrome P450 2D6 and 2C19 loci are at increased risk of developing adult acute leukaemia.
Roddam PL; Rollinson S; Kane E; Roman E; Moorman A; Cartwright R; Morgan GJ
Pharmacogenetics; 2000 Oct; 10(7):605-15. PubMed ID: 11037802
[TBL] [Abstract][Full Text] [Related]
7. Cytochrome P-450 2D6 and 2C19 polymorphisms and length of hospitalization in psychiatry.
Kropp S; Lichtinghagen R; Winterstein K; Schlimme J; Schneider U
Clin Lab; 2006; 52(5-6):237-40. PubMed ID: 16812949
[TBL] [Abstract][Full Text] [Related]
8. Seizures and myoclonus associated with antidepressant treatment: assessment of potential risk factors, including CYP2D6 and CYP2C19 polymorphisms, and treatment with CYP2D6 inhibitors.
Spigset O; Hedenmalm K; Dahl ML; Wiholm BE; Dahlqvist R
Acta Psychiatr Scand; 1997 Nov; 96(5):379-84. PubMed ID: 9395157
[TBL] [Abstract][Full Text] [Related]
9. Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response.
Tsai MH; Lin KM; Hsiao MC; Shen WW; Lu ML; Tang HS; Fang CK; Wu CS; Lu SC; Liu SC; Chen CY; Liu YL
Pharmacogenomics; 2010 Apr; 11(4):537-46. PubMed ID: 20350136
[TBL] [Abstract][Full Text] [Related]
10. Lack of polymorphism of the conversion of losartan to its active metabolite E-3174 in extensive and poor metabolizers of debrisoquine (cytochrome P450 2D6) and mephenytoin (cytochrome P450 2C19).
Sandwall P; Lo MW; Jonzon B; Dalén P; Furtek C; Ritter M; Alván G; McCrea J; Sjöqvist F
Eur J Clin Pharmacol; 1999 Jun; 55(4):279-83. PubMed ID: 10424320
[TBL] [Abstract][Full Text] [Related]
11. Selective effect of liver disease on the activities of specific metabolizing enzymes: investigation of cytochromes P450 2C19 and 2D6.
Adedoyin A; Arns PA; Richards WO; Wilkinson GR; Branch RA
Clin Pharmacol Ther; 1998 Jul; 64(1):8-17. PubMed ID: 9695714
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response.
Kirchheiner J; Nickchen K; Bauer M; Wong ML; Licinio J; Roots I; Brockmöller J
Mol Psychiatry; 2004 May; 9(5):442-73. PubMed ID: 15037866
[TBL] [Abstract][Full Text] [Related]
13. The crucial role of the therapeutic window in understanding the clinical relevance of the poor versus the ultrarapid metabolizer phenotypes in subjects taking drugs metabolized by CYP2D6 or CYP2C19.
de Leon J
J Clin Psychopharmacol; 2007 Jun; 27(3):241-5. PubMed ID: 17502769
[No Abstract] [Full Text] [Related]
14. The impact of Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes on suicide attempt and suicide risk-a European multicentre study on treatment-resistant major depressive disorder.
Höfer P; Schosser A; Calati R; Serretti A; Massat I; Kocabas NA; Konstantinidis A; Linotte S; Mendlewicz J; Souery D; Zohar J; Juven-Wetzler A; Montgomery S; Kasper S
Eur Arch Psychiatry Clin Neurosci; 2013 Aug; 263(5):385-91. PubMed ID: 23081704
[TBL] [Abstract][Full Text] [Related]
15. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir.
Mikus G; Schöwel V; Drzewinska M; Rengelshausen J; Ding R; Riedel KD; Burhenne J; Weiss J; Thomsen T; Haefeli WE
Clin Pharmacol Ther; 2006 Aug; 80(2):126-35. PubMed ID: 16890574
[TBL] [Abstract][Full Text] [Related]
16. Adverse drug reaction monitoring in Jena. Relevance of polymorphic drug metabolizing enzymes for inducing adverse drug reactions.
Hippius M; Buchardt C; Farker K; Kuhn UD; Reimann IR; Hoffmann A
Exp Toxicol Pathol; 2003 Jun; 54(5-6):417-21. PubMed ID: 12877354
[TBL] [Abstract][Full Text] [Related]
17. Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib.
Uttamsingh V; Lu C; Miwa G; Gan LS
Drug Metab Dispos; 2005 Nov; 33(11):1723-8. PubMed ID: 16103134
[TBL] [Abstract][Full Text] [Related]
18. Involvement of cytochromes P450 2D6, 2B6 and 2C19 in the metabolism of (-)-deprenyl and N-methyl,N-propargylphenylethylamine.
Rittenbach KA; Baker GB
Drug Metab Lett; 2007 Apr; 1(2):97-100. PubMed ID: 19356027
[TBL] [Abstract][Full Text] [Related]
19. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19.
de Leon J; Armstrong SC; Cozza KL
Psychosomatics; 2006; 47(1):75-85. PubMed ID: 16384813
[TBL] [Abstract][Full Text] [Related]
20. Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail".
Chainuvati S; Nafziger AN; Leeder JS; Gaedigk A; Kearns GL; Sellers E; Zhang Y; Kashuba AD; Rowland E; Bertino JS
Clin Pharmacol Ther; 2003 Nov; 74(5):437-47. PubMed ID: 14586384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
